Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02242942
Registration number
NCT02242942
Ethics application status
Date submitted
16/09/2014
Date registered
17/09/2014
Date last updated
5/06/2024
Titles & IDs
Public title
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Query!
Scientific title
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions
Query!
Secondary ID [1]
0
0
2014-001810-24
Query!
Secondary ID [2]
0
0
BO25323
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphocytic Leukemia, Chronic
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Chlorambucil
Treatment: Drugs - Venetoclax
Treatment: Drugs - Obinutuzumab
Experimental: Safety Run-in Obinutuzumab + Venetoclax - Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
Experimental: Obinutuzumab + Chlorambucil - Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
Experimental: Obinutuzumab + Venetoclax - Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
Treatment: Drugs: Chlorambucil
Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
Treatment: Drugs: Venetoclax
Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
Treatment: Drugs: Obinutuzumab
Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria
Query!
Assessment method [1]
0
0
PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of PD or death from any cause. Disease progression was characterized by at least one of the following: 1) >/= 50% increase in the absolute number of circulating lymphocytes to at least 5*10^9/L, 2) Appearance of new palpable lymph nodes (> 15 mm in longest diameter) or any new extra-nodal lesion; 3) >/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) >/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology.
Query!
Timepoint [1]
0
0
Baseline until disease progression or death up to approximately 3.75 years
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS) Based on Institutional Review Committee (IRC)-Assessments According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria
Query!
Assessment method [1]
0
0
PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause. Disease progression was characterized by at least one of the following: 1) >/= 50% increase in the absolute number of circulating lymphocytes to at least 5*10^9/L, 2) Appearance of new palpable lymph nodes (> 15 mm in longest diameter) or any new extra-nodal lesion; 3) >/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) >/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology.
Query!
Timepoint [1]
0
0
Baseline until disease progression or death up to approximately 3.75 years
Query!
Secondary outcome [2]
0
0
Percentage of Participants With an Overall Response (OR) at Completion of Treatment, as Determined by the Investigator According to IWCLL Criteria
Query!
Assessment method [2]
0
0
OR was defined as complete response (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and computed tomography (CT) scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: two of the following features for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L.
Query!
Timepoint [2]
0
0
At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a Complete Response Rate (CRR) at the Completion of Treatment Assessment as Determined by the Investigator According to IWCLL Criteria
Query!
Assessment method [3]
0
0
CRR was defined as the rate of a clinical response of CR or CRi according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri).
Query!
Timepoint [3]
0
0
At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood as Measured by Allele-Specific Oligonucleotide Polymerase Chain Reaction (ASO-PCR) at Completion of Treatment
Query!
Assessment method [4]
0
0
MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in peripheral blood.
Query!
Timepoint [4]
0
0
At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Treatment
Query!
Assessment method [5]
0
0
MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in bone marrow.
Query!
Timepoint [5]
0
0
At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)
Query!
Secondary outcome [6]
0
0
Overall Survival (OS)
Query!
Assessment method [6]
0
0
OS was defined as the time between the date of randomization and the date of death due to any cause.
Query!
Timepoint [6]
0
0
Baseline until death, up to approximately 10.75 years
Query!
Secondary outcome [7]
0
0
Percentage of Participants With MRD Negativity in Peripheral Blood as Measured by ASO-PCR at Completion of Combination Treatment Assessment
Query!
Assessment method [7]
0
0
MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in peripheral blood.
Query!
Timepoint [7]
0
0
Day 1 Cycle 9 or 3 months after last IV infusion, approximately 9 months
Query!
Secondary outcome [8]
0
0
Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Combination Treatment Assessment
Query!
Assessment method [8]
0
0
MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in bone marrow.
Query!
Timepoint [8]
0
0
Day 1 Cycle 9 or 3 months after last IV infusion at approximately 9 months
Query!
Secondary outcome [9]
0
0
Percentage of Participants With OR at Completion of Combination Treatment Response Assessment
Query!
Assessment method [9]
0
0
OR was defined as CR, CRi or PR according to IWCLL 2008 criteria. CR required all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. PR: two of the following features for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L.
Query!
Timepoint [9]
0
0
Day 1 Cycle 7 or 28 days after last IV infusion, approximately 6 months
Query!
Secondary outcome [10]
0
0
Duration of Objective Response (DOR)
Query!
Assessment method [10]
0
0
PD was defined as lymphadenopathy, >=50% increase in liver or spleen size, >=50% increase in lymphocyte count, transformation to a more aggressive histology or occurrence of cytopenia.
Query!
Timepoint [10]
0
0
Time from the first occurrence of a documented objective response to the time of PD as determined by the investigator or death from any cause, up to approximately 10.75 years
Query!
Secondary outcome [11]
0
0
Percentage of Participants By Best Response Achieved (CR, CRi, PR, Stable Disease (SD), or PD)
Query!
Assessment method [11]
0
0
CR: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: any two for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. PD: lymphadenopathy, >=50% increase in liver or spleen size, >=50% increase in lymphocyte count, transformation to a more aggressive histology or occurrence of cytopenia. SD: a non-response and used to characterize participants who did not achieve a CR or a PR, and who have not exhibited PD.
Query!
Timepoint [11]
0
0
Baseline up to the completion of treatment assessment 3 months after treatment completion (up to approximately 15 months)
Query!
Secondary outcome [12]
0
0
Event-Free Survival
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Time between date of randomization and the date of disease progression/relapse on the basis of investigator-assessment, death, or start of a new anti-leukemic therapy, up to 10.75 years
Query!
Secondary outcome [13]
0
0
Time to Next Anti-Leukemic Treatment
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Time between the date of randomization and the date of first intake of new anti-leukemic therapy, up to 10.75 years
Query!
Secondary outcome [14]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [14]
0
0
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.
Query!
Timepoint [14]
0
0
Up to approximately 10.75 years
Query!
Secondary outcome [15]
0
0
Percentage of Participants With CD19 + /CD5+ B Cells or CD14+ Monocytes
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Baseline up to approximately 10.75 years
Query!
Secondary outcome [16]
0
0
Percentage of Participants With Human-Anti-Human Antibodies
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Baseline up to approximately 10.75 years
Query!
Secondary outcome [17]
0
0
Percentage of Participants Recorded as Premature Study Withdrawals
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Up to approximately 10.75 years
Query!
Secondary outcome [18]
0
0
Plasma Concentrations of Venetoclax
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Pre-venetoclax dose (0 hour) and 4 hours post- venetoclax dose on Day 1 Cycle 4
Query!
Secondary outcome [19]
0
0
Serum Concentrations of Obinutuzumab
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Pre-obinutuzumab infusion (0 hour) and end of obinutuzumab infusion on Day 1 Cycle 4
Query!
Secondary outcome [20]
0
0
Change From Baseline in M.D. Anderson Symptom Inventory-CLL (MDASI-CLL) Score
Query!
Assessment method [20]
0
0
The MDASI-CLL is a questionnaire of 25 items related to CLL specific symptoms that a participant may have experienced in the past 24 hours. Participants were asked to rate the severity of 13 symptoms called mean core symptom severity (i.e., pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, and numbness or tingling), 6 disease-specific symptoms called mean module symptom severity (night sweats, fevers and chills, lymph node swelling, diarrhea, easy bruising or bleeding, and constipation) and 6 mean interference on life questions (i.e., general activity, walking, work, mood, relations with other people, and enjoyment of life) on a scale from 0 to 10 with 0 indicating that the symptom is "not present" or "did not interfere" with the participant's activities and 10 indicating "as bad as you can imagine" or "interfered completely". Scores were averaged (range 0 to 10) for each of three parts.
Query!
Timepoint [20]
0
0
Baseline up to approximately 10.75 years
Query!
Secondary outcome [21]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQC30)
Query!
Assessment method [21]
0
0
The EORTC QLQ-C30 is a validated and reliable self-report measure consisting of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional, and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), and a global health status/global quality-of-life scale. The remaining single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) assess the additional symptoms experienced by patients with cancer and the perceived financial burden of treatment. The 28 function and symptom items were scored on a 4-point scale that ranged from "not at all" to "very much," and the 2 global health status/global quality-of-life items were scored on a 7-point scale that ranged from "very poor" to "excellent." Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity).
Query!
Timepoint [21]
0
0
Baseline up to approximately 10.75 years
Query!
Secondary outcome [22]
0
0
Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D-3L)
Query!
Assessment method [22]
0
0
The EQ-5D-3L questionnaire is a generic, preference based health utility measure that assesses 5 health states (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is used to build a composite of the patient's health status. The EQ-5D-3L was employed in this study to calculate health utilities for economic modeling, which ranged 0-1. The EQ-5D-3L also contained a visual analog scale (VAS) to assess the participant's overall health, which ranged from 0-100 with a higher score indicating a worse health status.
Query!
Timepoint [22]
0
0
Baseline up to approximately 10.75 years
Query!
Eligibility
Key inclusion criteria
- Documented previously untreated CLL according to the International Workshop on Chronic
Lymphocytic Leukemia (IWCLL) criteria
- CLL requiring treatment according to IWCLL criteria
- Total Cumulative Illness Rating Scale (CIRS score) greater than (>) 6
- Adequate marrow function independent of growth factor or transfusion support within 2
weeks of screening as per protocol, unless cytopenia is due to marrow involvement of
CLL
- Adequate liver function
- Life expectancy > 6 months
- Agreement to use highly effective contraceptive methods per protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Transformation of CLL to aggressive Non-Hodgkin's lymphoma (Richter's transformation
or pro-lymphocytic leukemia)
- Known central nervous system involvement
- Participants with a history of confirmed progressive multifocal leukoencephalopathy
(PML)
- An individual organ/ system impairment score of 4 as assessed by the CIRS definition
limiting the ability to receive the treatment regimen of this trial with the exception
of eyes, ears, nose, throat organ system
- Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
- Inadequate renal function
- History of prior malignancy, except for conditions as listed in the protocol if
participants have recovered from the acute side effects incurred as a result of
previous therapy
- Use of investigational agents or concurrent anti-cancer treatment within the last 4
weeks of registration
- Participants with active bacterial, viral, or fungal infection requiring systemic
treatment within the last two months prior to registration
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
antibodies or known sensitivity or allergy to murine products
- Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the
excipients
- Pregnant women and nursing mothers
- Positive test results for chronic hepatitis B virus (HBV) infection (defined as
positive hepatitis B surface antigen [HBsAg] serology) or positive test result for
hepatitis C (hepatitis C virus [HCV] antibody serology testing)
- Participants with known infection with human immunodeficiency virus (HIV) or human
T-cell leukemia virus-1 (HTLV-1)
- Requires the use of warfarin, marcumar, or phenprocoumon
- Received agents known to be strong and moderate Cytochrome P450 3A inhibitors or
inducers within 7 days prior to the first dose of study drug
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/08/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
445
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [2]
0
0
Tweed Hospital - Tweed Heads
Query!
Recruitment hospital [3]
0
0
The Townsville Hospital - Douglas
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Royal Adelaide Hospital; Haematology Clinical Trials - Adelaide
Query!
Recruitment hospital [6]
0
0
Ashford Cancer Centre Research; Internal Medicine/Medical Oncology - Ashford
Query!
Recruitment hospital [7]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [8]
0
0
The Northern Hospital - Epping
Query!
Recruitment hospital [9]
0
0
Monash Medical Centre; Haematology - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
2485 - Tweed Heads
Query!
Recruitment postcode(s) [3]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
5035 - Ashford
Query!
Recruitment postcode(s) [7]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [8]
0
0
VIC 3076 - Epping
Query!
Recruitment postcode(s) [9]
0
0
3168 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Texas
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
Buenos Aires
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Innsbruck
Query!
Country [10]
0
0
Austria
Query!
State/province [10]
0
0
Wien
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
RS
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
SP
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Pleven
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Plovdiv
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Sofia
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Vratsa
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Alberta
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Nova Scotia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Croatia
Query!
State/province [20]
0
0
Zagreb
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Herlev
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
København Ø
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Roskilde
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Vejle
Query!
Country [25]
0
0
Estonia
Query!
State/province [25]
0
0
Tallinn
Query!
Country [26]
0
0
Estonia
Query!
State/province [26]
0
0
Tartu
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Besançon Cedex
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Caen
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Clermont Ferrand
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Creteil
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Dijon
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Grenoble
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Le Mans
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Lyon
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Montpellier
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Nantes
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Paris
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Rennes
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rouen
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Toulon
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Villejuif
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Aachen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Amberg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Berlin
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Dresden
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Essen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Esslingen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Frankfurt/Oder
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Freiburg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Göttingen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Heidelberg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Herne
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Koblenz
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Köln
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Landshut
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Munchen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Mutlangen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Mönchengladbach
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
München
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Neunkirchen/Saar
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Paderborn
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Regensburg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Stuttgart
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Tübingen
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Ulm
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Weiden
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Emilia-Romagna
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Lazio
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Lombardia
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Umbria
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Veneto
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Sinaloa
Query!
Country [73]
0
0
New Zealand
Query!
State/province [73]
0
0
Christchurch
Query!
Country [74]
0
0
New Zealand
Query!
State/province [74]
0
0
Dunedin
Query!
Country [75]
0
0
New Zealand
Query!
State/province [75]
0
0
Palmerston North
Query!
Country [76]
0
0
New Zealand
Query!
State/province [76]
0
0
Wellington
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Bialystok
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Chorzów
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Lodz
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Slupsk
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Wroclaw
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Bucharest
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Iasi
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Targu-mures
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Baskortostan
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Moskovskaja Oblast
Query!
Country [87]
0
0
Russian Federation
Query!
State/province [87]
0
0
Niznij Novgorod
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Rostov
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Tatarstan
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Penza
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Perm
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Navarra
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Tenerife
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Barcelona
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Madrid
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Salamanca
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Sevilla
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Toledo
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Valencia
Query!
Country [100]
0
0
Switzerland
Query!
State/province [100]
0
0
Bern
Query!
Country [101]
0
0
Switzerland
Query!
State/province [101]
0
0
Luzern
Query!
Country [102]
0
0
Switzerland
Query!
State/province [102]
0
0
Zürich
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Birmingham
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Boston,Lincolnshire
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Edinburgh
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Lincoln
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Southhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
AbbVie
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
German CLL Study Group
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, multicenter, randomized Phase III study is designed to compare the efficacy
and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab +
chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical
conditions. The time on study treatment was approximately one year and the follow-up period
will be up to 9 years.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02242942
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02242942
Download to PDF